Venture Partners Ix, Llcarc... Net Worth

The estimated Net Worth of Venture Partners Ix, Llcarc... is at least $2.41 Millón dollars as of 2 July 2019. Venture Llcarc owns over 200,000 units of Beam Therapeutics stock worth over $2,412,000 and over the last 5 years Venture sold BEAM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Llcarc BEAM stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Beam Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Venture bought 200,000 units of BEAM stock worth $3,200,000 on 2 July 2019.

The largest trade Venture's ever made was buying 200,000 units of Beam Therapeutics stock on 2 July 2019 worth over $3,200,000. On average, Venture trades about 11,111 units every 0 days since 2019. As of 2 July 2019 Venture still owns at least 100,000 units of Beam Therapeutics stock.

You can see the complete history of Venture Llcarc stock trades at the bottom of the page.

Insiders trading at Beam Therapeutics

Over the last 5 years, insiders at Beam Therapeutics have traded over $63,012,019 worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Llc Fmr y Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $1,019,987. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth $29,100.

What does Beam Therapeutics do?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Complete history of Venture Llcarc stock trades at Karuna Therapeutics Inc, Vir Biotechnology Inc y Beam Therapeutics

Beam Therapeutics executives and stock owners

Beam Therapeutics executives and other stock owners filed with the SEC include:

• Terry-Ann Burrell,
  Chief Financial Officer, Treasurer
• John Evans,
  Chief Executive Officer, Director
• Giuseppe Ciaramella,
  President, Chief Scientific Officer
• John M. Evans M.B.A.,
  CEO & Director
• Dr. Giuseppe Ciaramella Ph.D.,
  Pres & Chief Scientific Officer
• Terry-Ann Burrell M.B.A.,
  CFO & Treasurer
• Carole Ho,
  Independent Director
• Mark Fishman,
  Independent Director
• Graham Cooper,
  Independent Director
• Robert Nelsen,
  Independent Director
• Stephen Knight,
  Independent Director
• Kristina Burow,
  Independent Director
• Christine Swenson,
  Senior Vice President - Regulatory Affairs
• Manmohan Singh,
  Senior Vice President - Pharmaceutical Sciences and Delivery Technology
• David Liu,
  Co-Founder
• J. Keith Joung,
  Co-Founder
• Dr. Alexis Komor Ph.D.,
  Co-Founder
• Dr. Nicole Gaudelli Ph.D.,
  Co-Founder
• Suzanne Fleming,
  Chief Accounting Officer
• Dr. J. Keith Joung M.D., Ph.D.,
  Co-Founder
• Courtney Wallace,
  Chief Bus. Officer
• Susan O'Connor,
  Chief HR Officer
• Dr. Christine P. Bellon J.D., Ph.D.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Brian Riley,
  Sr. VP of Technical Operations
• Dr. Feng Zhang,
  Co-Founder
• John Maraganore,
  
• Kathleen E Walsh,
  
• Bethany J Cavanagh,
  SVP, Finance and Treasurer
• Group, Llc Green Jeremy Red...,
  
• Venture Partners Ix, Llcarc...,
  
• Venture Partners Ix, Llcarc...,
  
• Llc Fmr,
  
• Amy Simon,
  Chief Medical Officer
• Christine Bellon,
  Chief Legal Officer
• Christi Shaw,